Literature DB >> 22381091

Systemic mastocytosis--a systematic review.

Christen Lykkegaard Andersen1, Thomas Kielsgaard Kristensen, Marianne Tang Severinsen, Michael Boe Møller, Hanne Vestergaard, Olav J Bergmann, Hans Carl Hasselbalch, Ole Weis Bjerrum.   

Abstract

INTRODUCTION: The mast cell lives a hidden life, but it is implicated in several physiological reactions. Its ability to react to different stimuli impacts a variety of conditions such as asthma, atopic dermatitis, urticaria and anaphylaxis. It is not until recent decades that the evolution of the cell has been described and its fascinating biology has only recently been depicted. We here give a review of systemic mastocytosis in regards to cell biology, diagnostic approaches and clinical practice.
METHODS: A search was made in PubMed in August 2011 entering the keywords: mastocytosis, (systemic, cutaneous, aggressive), mast cell leukaemia, mast cell sarcoma, chromosome, mutation, haematology and treatment.
RESULTS: Mastocytosis is characterized by an abnormal proliferation of mast cells, which accumulate in one or several organ systems, primarily the skin and bone marrow. The disease is clinically heterogeneous and varies from a relatively benign condition with isolated cutaneous lesions to a very aggressive systemic condition with a grave prognosis. The condition affects men and women equally. Children are especially affected by the cutaneous form. In most children, the condition will improve or remit spontaneously before adulthood. Mastocytosis in adults, however, is more often systemic and tends to persist.
CONCLUSION: Patients with mastocytosis represent a heterogeneous group in terms of clinical presentation, management and prognosis. Furthermore, a range of medical specialties serve as the primary entrance to health services, which can be a challenge in respect of achieving uniform management. In order to improve diagnostics and management of systemic mastocytosis, the European Competence Network on Mastocytosis has been established. Patients under suspicion of systemic mastocytosis should be conferred with or referred to a haematological and a dermatological/allergological department.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22381091

Source DB:  PubMed          Journal:  Dan Med J        ISSN: 2245-1919            Impact factor:   1.240


  5 in total

1.  The care pathway for children with urticaria, angioedema, mastocytosis.

Authors:  Giuliana Ferrante; Valeria Scavone; Maria Concetta Muscia; Emilia Adrignola; Giovanni Corsello; Giovanni Passalacqua; Stefania La Grutta
Journal:  World Allergy Organ J       Date:  2015-02-02       Impact factor: 4.084

Review 2.  Critical care management of systemic mastocytosis: when every wasp is a killer bee.

Authors:  Hinke Y van der Weide; David J van Westerloo; Walter M van den Bergh
Journal:  Crit Care       Date:  2015-06-03       Impact factor: 9.097

3.  Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.

Authors:  Andreas Hochhaus; Michele Baccarani; Francis J Giles; Philipp D le Coutre; Martin C Müller; Andreas Reiter; Helene Santanastasio; Mimi Leung; Steven Novick; Hagop M Kantarjian
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-23       Impact factor: 4.553

Review 4.  Mast Cell Clonal Disorders: Classification, Diagnosis and Management.

Authors:  Merel C Onnes; Luciana K Tanno; Joanne N G Oude Elberink
Journal:  Curr Treat Options Allergy       Date:  2016-11-08

5.  Two cases of mimics of bone metastasis in breast cancer.

Authors:  Aung Win Tin; John Hardman; Geoffrey Naisby
Journal:  BJR Case Rep       Date:  2017-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.